(Q42178340)

English

Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial

scientific article published on 21 November 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 October 2017

Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial (English)

1 reference

Europe PubMed Central

18 October 2017

Joanne M. Langley

object named as

Joanne M Langley

1

0 references

Shelly A McNeil

object named as

Shelly McNeil

7

0 references

Scott A Halperin

4

object named as

Scott A Halperin

1 reference

Europe PubMed Central

18 October 2017

Louise Frenette

2

object named as

Louise Frenette

1 reference

Europe PubMed Central

18 October 2017

8

object named as

Mamadou Dramé

1 reference

Europe PubMed Central

18 October 2017

author name string

Robert Jeanfreau

3

1 reference

Europe PubMed Central

18 October 2017

Michael Kyle

5

1 reference

Europe PubMed Central

18 October 2017

Laurence Chu

6

1 reference

Europe PubMed Central

18 October 2017

Philippe Moris

9

1 reference

Europe PubMed Central

18 October 2017

Louis Fries

10

1 reference

Europe PubMed Central

18 October 2017

David W Vaughn

11

1 reference

Europe PubMed Central

18 October 2017

language of work or name

0 references

publication date

21 November 2014

1 reference

Europe PubMed Central

18 October 2017

1 reference

Europe PubMed Central

18 October 2017

33

1 reference

Europe PubMed Central

18 October 2017

4

1 reference

Europe PubMed Central

18 October 2017

559-567

1 reference

Europe PubMed Central

18 October 2017

Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Allocation of patients to treatment groups in a controlled clinical study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Immunofluorescence analysis of T-cell responses in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Strategies for mitigating an influenza pandemic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Influenza drift and epidemic size: the race between generating and escaping immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.11.018

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2014.11.018

1 reference

Europe PubMed Central

18 October 2017

1 reference

Europe PubMed Central

18 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42178340&oldid=1935353753"